BALPHARMA2024-10-012024-12-31 BALPHARMA2024-10-012024-12-31 BALPHARMA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member BALPHARMA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member BALPHARMA2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524824 BALPHARMA NOTLISTED Bal Pharma Limited Equity 2024-04-01 2025-03-31 2025-02-13 2025-01-23 INR Lakhs Third quarter 17:00:00 17:40:00 2025-02-13 2025-02-13 Not applicable Single segment Pharmaceuticles 2024-10-01 2024-12-31 Unaudited Consolidated 731544000.00 5064000.00 736608000.00 375828000.00 35438000.00 -42721000.00 159751000.00 50129000.00 26854000.00 125666000.00 730945000.00 5663000.00 0.00 5663000.00 1448000.00 -964000.00 484000.00 0.00 5179000.00 0.00 0.00 0.00 0.00 5179000.00 0.00 5179000.00 4812000.00 367000.00 0.00 0.00 159209000.00 10 0.33 0.33 0.00 0.00 0.33 0.33 Notes: 1. The above unaudited consolidated financial results of the company have been reviewed by the Audit Committee and approved by the Board of Directotrs at their respective meetings held on 13.02.2025. 2. The consolidated financial results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules , 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013, Read with relevant rules issued thereunder and other recognised accounting practices and policies to the extent applicable. The unaudited consolidated financial results relate to Bal Pharma Limited, its subsidiaries (together constitute group) joint venture and Associates are prepared by applying IND AS 110 - consolidated Financial statements , and IND AS 28 - investments in Associates & joint ventures. 3. The group has not received any intimation or information with regard to its vendor registration as Micro, Small and Medium enterprices . Accordingly the entire dues to vendors has been classified as payable to other than MSME. 4.The Company has outstanding recoverability of Rs.869.89+ Lkhs and Rs. 152.23 Lkhs from its subsidiaries Lifezen Healthcare Private Limited and Balance Clinics LLP. The said subsidiaries have incurred losses and have a negative networth. However the management is confident that with infusion of additional funds , introduction of new brands and renewed marketing, internal restructuring, the companies can be revived and the amounts be recovered. 5.The Company has only one reportable segment namely Pharmaceuticals . 6.The Company has filed application with NCLT for merger of Golden Drugs Pvt Ltd , a wholly owned subsidiary of the Company. 7.Previous period figures have been regrouped/rearranged wherever considered necessary to confirm to the period presentation Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 2212071000.00 11200000.00 2223271000.00 1111829000.00 80884000.00 -53508000.00 469097000.00 129048000.00 75906000.00 384574000.00 2197830000.00 25441000.00 0.00 25441000.00 11609000.00 -4350000.00 7259000.00 0.00 18182000.00 0.00 0.00 0.00 0.00 18182000.00 0.00 18182000.00 17822000.00 359000.00 0.00 0.00 159209000.00 10 1.14 1.14 0.00 0.00 1.14 1.14 Other Expenses 125666000.00 Other Expenses 384574000.00